Aaron Rosenberg
Known title: Chief Financial OfficerCIK: 0002031182
Associated companies
Transaction History
| ONC | ▼ Sell | Open Market | 1,157 | $362K | 8/3/2026 | View on chart |
| ONC | ▲ Buy | Grant | 71,175 | $0 | 6/11/2026 | View on chart |
| ONC | ▼ Sell | Open Market | 631 | $163K | 6/11/2026 | View on chart |
| ONC | ▲ Buy | Grant | 79,014 | $0 | 3/6/2026 | View on chart |
| ONC | ▲ Buy | Grant | 40,573 | $0 | 3/6/2026 | View on chart |
| ONC | ▼ Sell | Open Market | 1,190 | $346K | 8/1/2025 | View on chart |
| ONC | ▲ Buy | Grant | 63,674 | $0 | 6/10/2025 | View on chart |
| ONC | ▲ Buy | Grant | 48,581 | $0 | 3/5/2025 | View on chart |
| ONC | ▲ Buy | Grant | 118,547 | $0 | 8/9/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List
BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.